Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|July 2, 2003
- Pharmaceutical Technology-07-02-2003
- Volume 27
- Issue 7
Capacity Worries Fade for Biomanufacturing
Author(s)Jim Miller
The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.
Advertisement
Articles in this issue
about 23 years ago
July 2003about 23 years ago
The Push for Generics Challenges Manufacturersabout 23 years ago
Emerging Research Opportunities in Oral Inhalation Technologyabout 23 years ago
Preventing Metal ContaminationAdvertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement